Taysha

View All

recent-pharma-news-and-updates-for-astrazeneca-sanofi-taysha
Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities

Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M  Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million.  TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to tre...

Find More